Hemogenyx Pharmaceuticals Plc

LSE:HEMO.L

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

Location

United Kingdom

Market Cap

USD 10.54 M

Share Price

USD 2.30

Avg Daily Volume

45,155

Change (1 day)

-0.92%

Change (1 year)

13,553.90%

Change (YTD)

-54.70%

Hemogenyx Pharmaceuticals Plc Revenue for the year ending December 31, 2024: USD 0.00

Hemogenyx Pharmaceuticals Plc Revenue is USD 0.00 for the year ending December 31, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Hemogenyx Pharmaceuticals Plc Revenue for the year ending December 31, 2023 was USD 0.00.
Hemogenyx Pharmaceuticals Plc Revenue for the year ending December 31, 2022 was USD 0.00.
Hemogenyx Pharmaceuticals Plc Revenue for the year ending December 31, 2021 was USD 0.00.
Hemogenyx Pharmaceuticals Plc Revenue for the year ending December 31, 2020 was USD 0.00.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

LSE: HEMO.L

Hemogenyx Pharmaceuticals Plc

CEO	Dr. Vladislav Sandler Ph.D.
IPO Date	Nov. 9, 2015
Location	United Kingdom
Headquarters	60 Gracechurch Street
Employees	16
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials

Description

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.